International Isotopes Inc. (OTCMKTS:INIS) is a U.S.-based supplier of medical and industrial radioisotopes, stable isotopes, and related radiochemical products. Headquartered in Idaho Falls, Idaho, the company operates a portfolio of production and service facilities that deliver key isotopes used in diagnostic imaging, cancer therapy, and industrial applications. Its product lineup includes molybdenum-99, iodine-131, and lutetium-177 for nuclear medicine, as well as custom stable isotopes for research and manufacturing processes.
In addition to isotope production, International Isotopes provides radiopharmaceutical and analytical laboratory services through its subsidiary network. These services support pharmaceutical development, quality control testing, and environmental monitoring. The company’s integrated approach—from isotope sourcing and processing to end-user product formulation—enables tailored solutions for hospitals, research institutions, and industrial clients across North America, Europe, and Asia Pacific regions.
Founded in 1995, International Isotopes has expanded through strategic partnerships, facility upgrades, and regulatory approvals to enhance production capacity and diversify its product offerings. A key milestone was the establishment of a proprietary molybdenum-99 production process that reduces reliance on aging nuclear reactors, positioning the company to address global shortages in critical medical isotopes.
Under the leadership of CEO Marco Milea, International Isotopes emphasizes safety, regulatory compliance, and process innovation. The management team brings decades of experience in nuclear chemistry, radiopharmaceutical development, and commercial isotope distribution, guiding the firm’s growth strategy and commitment to supply continuity in the rapidly evolving nuclear medicine and research markets.
AI Generated. May Contain Errors.
